Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
Showing 721–780 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
…demic medical centre, both patients were treated with localised yttrium-90 (Y90) radioembolisation therapy, and neither underwent liver tr…
… 1 to amine-coated iron-oxide nanoparticles functionalized with Sulfo-SMCC. Cells were expanded in the presence of CD4 subset-polarizing m…
…without additional treatment.Results Mice treated with tAPC and STING agonist NPs exhibited slower tumor progression and extended sur…
…, Lao CD, De Menezes JJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med . 2022;386:24–34. …
…The unique mechanism of action of immune checkpoint inhibitors (ICI) can lead to auto-inflammatory events, potentially involving an…
…77.0412Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J M…
…0 in T and B cells, respectively. In the syngeneic tumor model, Glofitamab analog treatment significantly suppressed tumor growth. Toxicit…
…odynamic data to predict human PK and inform dose selection for bispecific antibodies. The approach serves as a viable alternative to animal testing,…
…ffinized and processed before being stained with a nuclear dye, TO-PRO-3, and Eosin, a cytoplasmic/structural dye. Samples were opticall…
…iota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: preliminary …
…biotas failed to respond to a-CTLA-4 treatment, and addition of B. uniformis restores this response, which is dependent on NK cells. We furt…
…mmer R, Butler MO, Hill AG, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. New England Journal of Me…